Pet healthcare spending has dramatically increased, doubling over the past five years and reaching an estimated $39.8 billion in 2024. This surge in expenses reflects a significant shift in how pet owners prioritize the health and well-being of their animals, leading to a thriving market for companies involved in pet healthcare. Projections suggest that this sector could grow to $112 billion by 2030, indicating a robust future for businesses within the industry.
The overall U.S. pet market is valued at approximately $157 billion, while the global pet healthcare and products sector is on track to exceed $273 billion this year. This growth has set the stage for several companies, including Zoetis Inc (NYSE: ZTS), IDEXX Laboratories (NASDAQ: IDXX), Elanco Animal Health Incorporated (NYSE: ELAN), Trupanion Inc (NASDAQ: TRUP), and PetVivo Holdings (OTCQX: PETV), to capitalize on favorable market conditions leading into 2026.
The Evolution of Pet Spending
Since the 1960s, pets have transitioned from being viewed as mere companions to being considered integral family members. This change in perspective has resulted in a substantial increase in spending on various aspects of pet care, particularly in healthcare. The range of veterinary services now rivals that offered to humans in many emerging markets, prompting the growth of a dedicated pet insurance sector.
Zoetis Inc stands as a dominant player in veterinary medications and vaccinations. The company also supplies pharmaceuticals to the livestock industry, emphasizing its broad market influence. In 2024, Zoetis reported an 8% increase in revenue, totaling $9.26 billion, with its pet segment accounting for a robust 13% growth to reach $6.28 billion. With a net income of $2.5 billion in 2024, Zoetis has consistently exceeded analysts’ expectations for four consecutive quarters and offers a dividend yield of 1.56%.
The company has invested over $1.7 billion in U.S. manufacturing facilities since 2017, including a $590 million plant near Atlanta, Georgia, set to open in 2029. This facility will focus on vaccine production and is expected to create 100 new jobs.
IDEXX Laboratories and Other Key Players
While medications are crucial, diagnostics play a vital role in pet healthcare. IDEXX Laboratories, headquartered in Westbrook, Maine, specializes in diagnostics for pets, livestock, poultry, dairy, and water testing. The company has seen remarkable stock performance, with shares climbing from $320 in August 2022 to $701 recently, reflecting a 62% increase over the past year.
IDEXX’s revenue is split roughly 60% domestic and 40% international. The company’s recent innovations include the inVue Dx Cellular Analyzer, which utilizes artificial intelligence to deliver rapid diagnostic results, and a new screening process for canine lymphoma. Institutional investors hold over 96% of IDEXX shares, underscoring strong market confidence.
Another significant player, Elanco Animal Health, based in Indianapolis, has a well-established history, having spun off from Eli Lilly and Company in 2019. Elanco offers over 200 products across more than 90 countries. Noteworthy products include Coredelio Quattro, which achieved $100 million in sales in September 2025, and Zenrelia, an allergy treatment used in over 8,000 U.S. clinics.
Elanco’s stock has surged 275% since April 2025, recovering from a low of $8.00 per share to about $22.00. The company anticipates a 9% organic revenue growth and has raised its full-year revenue guidance by $100 million.
Trupanion Inc has emerged as a leader in pet insurance, offering coverage across the U.S., Canada, Puerto Rico, and Australia. The company has over 1 million policies in force and reported a 12.1% year-on-year revenue growth in its latest financial report. CEO Margaret Tooth announced plans to invest more in acquiring new customers, bolstered by a solid market position.
In recent years, PetVivo Holdings has gained attention for its innovative treatments for joint injuries in pets. The company has developed a product called Spryng, designed to assist in healing joint issues, which has garnered interest from pet insurers like Trupanion. PetVivo’s stock has increased by 165.31% over the past year, further illustrating the growing demand for advanced veterinary treatments.
As pet healthcare spending escalates and innovations continue to emerge, the landscape for companies in this sector appears promising. The ongoing trend of pets being viewed as family members is likely to sustain high demand for healthcare services, creating opportunities for growth among these key players in the market.
